touchONCOLOGY joins Professor Jean-Luc Van Laethem (Erasme University Hospital, Brussels, Belgium), principle investigator of the KEYNOTE-224 study, to discuss the updated results for pembrolizumab monotherapy as first-line therapy for advanced hepatocellular carcinoma.
Questions
1. What were the objectives of the KEYNOTE-224 study? (00:38-01:33)
2. What have previous study findings taught us about the clinical utility of pembrolizumab monotherapy as therapy for advanced hepatocellular carcinoma (HCC)? (01:33-02:52)
3. Could you give us an overview of the latest results from the KEYNOTE-244 study? (02:52-04:00)
4. Where do you place pembrolizumab in future treatment paradigms for HCC? (04:00-05:12)
5. How can outcomes with pembrolizumab in this indication be further improved and what future studies are planned? (05:12-06:03)
Disclosures: Jean-Luc Van Laethem has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
